Apellis Pharmaceuticals (APLS) PT Raised to $46 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 9 | New: 1
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 9 | New: 1
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $46.00 (from $44.00) while maintaining a Neutral rating.
You May Also Be Interested In
- TeamViewer (TMV:GR) (TMVWY) PT Lowered to EUR6.50 at Deutsche Bank
- AMD (AMD) PT Raised to $725 at Stifel
- Ferrari NV (RACE:IM) (RACE) PT Raised to EUR465 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
